Clinical Guidelines

Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...

Share

  • 1

    Epcoritamab-R2 reduced disease progression risk by 80% compared to R2 alone.

  • 2

    The study involved 488 relapsed follicular lymphoma patients.

  • 3

    Epcoritamab enhances progression-free survival and overall response rates.

  • 4

    Outpatient treatment administration is possible, increasing patient access.

  • 5

    Safety profiles showed manageable side effects, mainly neutropenia.

  • 6

    Results suggest a shift in standard-of-care treatment for follicular lymphoma.

Original Source(s)

Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...

  • by Caroline Helwick

  • February 20, 2026

  • 9 min

Related Content

Delivering Big Ideas from ASH 2025

At Fox Chase Cancer Center and Temple University Hospital, it’s “in the blood” of our residents and Fellows to develop innovative scientific ideas that significantly affect the way blood diseases are diagnosed and treated. Here is the latest from ASH 2025:

  • by

  • February 17, 2026

  • 1 min
Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes

Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.

  • by

  • February 13, 2026

  • 12 min
Smarter Digital Morphology Triage

A diffusion-based approach aims to handle domain shifts, slide variability, and rare cell appearances

  • January 30, 2026

  • 3 min